3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
25
Precursor Cell Lymphoblastic Leukemia-Lymphoma
21
Lymphoma
19
Leukemia, Myeloid, Acute
18
Myelodysplastic Syndromes
17
Lymphoma, Non-Hodgkin
14
Neoplasms, Plasma Cell
12
Leukemia
12
Neuroblastoma
11
Leukemia, Lymphocytic, Chronic, B-Cell
11
Lymphoma, Large B-Cell, Diffuse
9
Hodgkin Disease
9
Recurrence
7
Melanoma
7
Lymphoma, Mantle-Cell
7
Hematologic Neoplasms
7
Burkitt Lymphoma
7
Sarcoma
6
Ovarian Neoplasms
6
Myeloproliferative Disorders
6
Lymphoma, Large-Cell, Immunoblastic
6
Lymphoma, Follicular
6
Sarcoma, Ewing
5
Neoplasm Metastasis
5
Medulloblastoma
5
Lymphoma, B-Cell, Marginal Zone
5
Liver Neoplasms
5
Wilms Tumor
4
Rhabdomyosarcoma
4
Retinoblastoma
4
Interventions
venetoclax
1
vandetanib
1
tremelimumab
1
ricolinostat
1
pomalidomide
1
pembrolizumab
1
pazopanib
1
niraparib
1
ibrutinib
1
enzastaurin
1
durvalumab
1
copanlisib
1
brigatinib
1
binimetinib
1
avasopasem manganese
1
abexinostat
1
Transplantation, Autologous
1
Steroids
1
Melphalan
1
Interleukin-2
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Dexamethasone
1
Blood Specimen Collection
1
Biopsy
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Disease Progression
×
Melphalan
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts